ALMS

Alumis

This company develops oral therapies and precision medicines for patients with immune-mediated disorders including plaque psoriasis and systemic lupus erythematosus.

Immunic Therapeutics

The company develops oral therapies for chronic inflammatory and autoimmune diseases for patients with neurological and gastrointestinal conditions.

Clinical-stage biotech

This company develops immunomodulatory recombinant protein therapies to treat autoimmune and chronic inflammatory diseases for patients with conditions such as chronic inflammatory demyelinating polyneuropathy.

VTYX

This biopharmaceutical company develops oral small-molecule medicines for patients with autoimmune, inflammatory, cardiovascular and neurodegenerative diseases.

SLRN

This biopharmaceutical company develops and commercialises medicines for patients with immune-mediated and rare diseases.

Alba Therapeutics Corp

This biopharmaceutical company develops oral peptide therapeutics to treat autoimmune and inflammatory conditions, such as celiac disease, for patients with gastrointestinal disorders.

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

Alector

This biopharmaceutical company develops therapies for neurodegenerative diseases using a blood-brain barrier delivery platform for patients with conditions including ALS and Parkinson’s.